Innate Pharma股票討論區

$Innate Pharma(IPHA.US)$
NEWS
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monothe...

$Innate Pharma(IPHA.US)$
NEWS
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024.
🔸Promising preclinical data for IPH4...

$Innate Pharma(IPHA.US)$
NEWS
Innate Pharma SA (Nasdaq: IPHA) executives to attend Van Lanschot Kempen conference in Amsterdam on April 16-17, 2024.

$Innate Pharma(IPHA.US)$ Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.10) per share. This is a 87.2 percent increase over losses of $(0.75) per share from the same period last year. The company reported $66.35 million in sales this quarter. This is a 12.71 percent increase over sales of $58.87 million the same period last year.

$輝瑞(PFE.US)$  Phase 2
$Leap Therapeutics(LPTX.US)$  Phase 2
$Vera Therapeutics(VERA.US)$  Phase 2b
$4D Molecular Therapeutics(FDMT.US)$  Phase 2
$Adverum Biotechnologies(ADVM.US)$  Phase 2
$Denali Therapeutics(DNLI.US)$  Phase 2
$Akero Therapeutics(AKRO.US)$  Phase 2b
$Spruce Biosciences(SPRB.US)$  Phase 2
$Xencor(XNCR.US)$  Phase 2
$阿里拉姆制藥(ALNY.US)$  Phase 2
$Harmony Biosciences(HRMY.US)$  Phase 2
$Annexon(ANNX.US)$  Phase 2a
$Roivant Sciences(ROIV.US)$...

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...

$Innate Pharma(IPHA.US)$ Filed for up to 200M Shelf!

$Innate Pharma(IPHA.US)$ So ok yeah its up today! got a bit of that reversal confirmation! but OMG what a terribly ugly 5 minute chart! Hehehe

$Innate Pharma(IPHA.US)$ I think i may call that 3 stars in the south on the daily? Hmm News, and a common reversal pattern! Yes watching very close for a bit of a pullback and volume? And i just may have to try this if i get confirmation? With SL tight! Just thinking outloud! hehehe

$Innate Pharma(IPHA.US)$ Sanofi Exercises Option to License 4th NK Cell Engager Program in Solid Tumors From Innate Pharma's ANKET Platform
Sanofi (SNY) has exercised its option to license its fourth natural killer cell engager program in solid tumors from Innate Pharma's (IPHA) Antibody-based NK Cell Engager Therapeutics, or ANKET, platform, according to a Tuesday statement.
The ANKET is Innate's platform for developing multi-specific natural killer...